Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Sanara MedTech ( (SMTI) ).
Sanara MedTech Inc. has prepared a new investor presentation summarizing its priorities, strategy and anticipated revenue for the 2026 fiscal year, which it plans to use in meetings with investors and analysts, including at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026. The company emphasized that the materials are furnished, not filed, under securities regulations, limiting associated liabilities and clarifying that the information should be interpreted within the context of its existing SEC disclosures and may be updated at management’s discretion.
The most recent analyst rating on (SMTI) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Sanara MedTech stock, see the SMTI Stock Forecast page.
Spark’s Take on SMTI Stock
According to Spark, TipRanks’ AI Analyst, SMTI is a Neutral.
Sanara MedTech’s overall score is primarily impacted by its financial performance challenges, including profitability and cash flow issues. While the earnings call showed some positive growth, technical indicators suggest a bearish trend, and valuation metrics are weak due to ongoing losses.
To see Spark’s full report on SMTI stock, click here.
More about Sanara MedTech
Sanara MedTech Inc. is a healthcare company that regularly communicates with investors and analysts through formal presentations and Securities and Exchange Commission filings. The company uses investor presentations to outline its strategic priorities, operational focus and revenue expectations for upcoming fiscal periods within the broader U.S. healthcare market.
Average Trading Volume: 54,897
Technical Sentiment Signal: Sell
Current Market Cap: $182.6M
For an in-depth examination of SMTI stock, go to TipRanks’ Overview page.